JP2005528351A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528351A5
JP2005528351A5 JP2003574110A JP2003574110A JP2005528351A5 JP 2005528351 A5 JP2005528351 A5 JP 2005528351A5 JP 2003574110 A JP2003574110 A JP 2003574110A JP 2003574110 A JP2003574110 A JP 2003574110A JP 2005528351 A5 JP2005528351 A5 JP 2005528351A5
Authority
JP
Japan
Prior art keywords
group
mixtures
chelating agent
activated protein
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/005046 external-priority patent/WO2003075834A2/en
Publication of JP2005528351A publication Critical patent/JP2005528351A/ja
Publication of JP2005528351A5 publication Critical patent/JP2005528351A5/ja
Pending legal-status Critical Current

Links

JP2003574110A 2002-03-08 2003-02-27 活性化プロテインc製剤 Pending JP2005528351A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36336402P 2002-03-08 2002-03-08
PCT/US2003/005046 WO2003075834A2 (en) 2002-03-08 2003-02-27 Activated protein c formulations

Publications (2)

Publication Number Publication Date
JP2005528351A JP2005528351A (ja) 2005-09-22
JP2005528351A5 true JP2005528351A5 (enExample) 2006-04-13

Family

ID=27805279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574110A Pending JP2005528351A (ja) 2002-03-08 2003-02-27 活性化プロテインc製剤

Country Status (6)

Country Link
US (1) US20050143283A1 (enExample)
EP (1) EP1485121A4 (enExample)
JP (1) JP2005528351A (enExample)
AU (1) AU2003213146A1 (enExample)
CA (1) CA2475738A1 (enExample)
WO (1) WO2003075834A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101438839B1 (ko) * 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 (glp-1) 약제학적 제제
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
KR20150110607A (ko) * 2013-01-14 2015-10-02 아페이론 바이오로직스 아게 변형된 ace2 폴리펩티드
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
NZ788906A (en) * 2016-06-01 2025-07-25 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
DE3607559A1 (de) * 1986-03-07 1987-09-10 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインc調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインcもしくは活性化プロテインcの安定化方法及び安定化組成物
PL195642B1 (pl) * 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインcの不活性化を抑制するための銅キレート剤の使用

Similar Documents

Publication Publication Date Title
CA2288143A1 (en) Activated protein c formulations
JP2005526084A5 (enExample)
JP2003522154A5 (enExample)
JP2009524595A5 (enExample)
JP2006523695A5 (enExample)
JP2005519914A5 (enExample)
JP2019509311A5 (enExample)
JP2015535237A5 (enExample)
JP2024099628A5 (enExample)
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
RU2009143991A (ru) Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
EP2197283B1 (en) Formulations for preservation of rota virus
JP2014139229A5 (enExample)
BRPI0409450B8 (pt) composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos
JP2010513487A5 (enExample)
JP2005528351A5 (enExample)
JP2003505482A (ja) ロタウイルスワクチン調合物
JP2015134795A5 (enExample)
JP2019512012A5 (enExample)
JP2002249441A (ja) 血液凝固第vii因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤
JP2009502972A (ja) タンパク質凝集を抑制する製剤
RU2004133349A (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
JP4332694B2 (ja) 水溶性乾燥組成物
ES2343432T3 (es) Preparado granular que contiene un compuesto de biguanida.
JP2003522782A5 (enExample)